Abstract Alzheimer's disease (AD), a debilitating neurodegenerative disease is caused by aggregation and accumulation of a 39-43 amino acid peptide (amyloid b or Ab) in brain parenchyma and cerebrovasculature. The rational approach would be to use drugs that interfere with Ab-Ab interaction and disrupt polymerization. Peptide ligands capable of binding to the KLVFF (amino acids 16-20) region in the Ab molecule have been investigated as possible drug candidates. Retro-inverso (RI) peptide of this pentapeptide, ffvlk, has been shown to bind artificial fibrils made from Ab with moderate affinity. We hypothesized that a 'detox gel', which is synthesized by covalently linking a tetrameric version of RI peptide ffvlk to poly(ethylene glycol) polymer chains will act like a 'sink' to capture Ab peptides from the surrounding environment. We previously demonstrated that this hypothesis works in an in vitro system. The present study extended this hypothesis to an in vivo mouse model of AD and determined the therapeutic effect of our detox gel. We injected detox gel subcutaneously to AD model mice and analyzed brain levels of Ab-42 and improvement in memory parameters. The results showed a reduction of brain amyloid burden in detox gel treated mice. Memory parameters in the treated mice improved. No undesirable immune response was observed. The data strongly suggest that our detox gel can be used as an effective therapy to deplete brain Ab levels. Considering recent abandonment of failed antibody based therapies, our detox gel appears to have the advantage of being a non-immune based therapy.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disease and is the most common cause of dementia among people age 65 or older. Although the etiology of AD is not completely understood, amyloid beta peptide (Ab), the major component of senile plaques found in AD brains, is implicated in the pathogenesis of AD (Small et al. 2001) . Amyloid beta aggregations as cytotoxic inclusions or amyloid-like plaques in the brain parenchyma and cerebrovasculature is perceived to be central to the pathogenesis of AD. Amyloid associated with Alzheimer's disease consists of thin fibrils of polymerized Ab with an ordered b-sheet pattern in AD brains. The actual form of Ab that causes the damage is still uncertain, but is most likely a small dimeric or higher oligomeric species with internal b-sheet structure (Selkoe 1996) . It has been well demonstrated that compounds intended to block b-sheet formation will inhibit the formation of both amyloid fibrils and smaller oligomers, and block Ab toxicity toward neurons in in vitro and in animal models (Soto et al. 1998) . Ab binds to itself at residues 12-23. This region has been the basis for the synthesis of numerous small peptides as b-sheet blockers (Tjernberg et al. 1997) . Therefore, the rational pharmacological approach would be to use drugs that interfere with Ab-Ab interaction and polymerization. Tjernberg et al. (1996) deduced that the KLVFF segment in the truncated native Ab sequence was of critical importance in the polymerization of amyloid fibril. Peptides that incorporate this sequence will bind Ab and block fibril formation of . Peptides composed of D-amino acids of this sequence were found to be as effective in preventing amyloid fibril formation and with increased protease resistance.
Retro-inversion technology involves reversing the primary sequence of a peptide and replacing L-amino acids with D-amino acids. This development in peptidomimetics, based on peptide-bond reversal and inversion of chirality has presented an increased possibility of designing superior peptide-based therapeutics (Kokkoni et al. 2006) . Researchers found that the retro-inverso (RI) peptide, ffvlk, of the native sequence KLVFF binds artificial fibrils made from Ab with moderate affinity and that increasing the copy number of peptide has an additive effect on its affinity for Ab (Zhang et al. 2003) .
A recent concept based on ''peripheral sink'' hypothesis was introduced for inhibiting the accumulation of plaques in the brain. This model is based on the finding that Ab peptides can exit from the brain into the periphery (Strazielle et al. 2000) . Thus, it might be possible to tip the balance toward removal rather than accumulation of Ab in the CNS, based on the premise that Ab equilibrates between the CNS and the periphery. Two publications tested this hypothesis. In an earlier study (DeMattos et al. 2002) , monoclonal antibodies, which cannot cross the blood-brain barrier (BBB) was injected intravenously into AD mice. In the latter study (Matsuoka et al. 2003) , they injected a high-molecular-weight protein or a small lipid, both previously known to avidly bind to Ab. Indeed, both reported depletion of plaques in the brain. Any of these three substances could possibly slow down or halt AD progression. Therefore, our therapeutic strategy and therapeutic reagent does not have to cross the BBB. Instead, the toxic Ab peptides will cross the BBB, and will be captured in the periphery. This ''sequestration'' was tested using Congo red (Matsuoka et al. 2003) . After 3 weeks, they reported that it did ''not substantially alter brain Ab load.'' This failure suggested optimizing Ab binding agents for greater affinity to Ab peptides. Sagare et al., on the contrary proved altering brain Ab loads by using circulating lipoprotein receptors (sLRP) as a peripheral sink. In this study, circulating sLRP caused Ab efflux from brain to plasma and sequestered the amyloid from plasma (Sagare et al. 2007) .
We have developed a novel therapeutic combining the features of the Ab binding agents with the properties of the subcutaneous PEG based hydrogel drug delivery and called it the ''detox gel''. The principles of the peripheral sink approach to deplete the brain of toxic amyloid peptides using the detox gel was explored. We showed that these detox gels containing the tetrameric version of the ffvlk peptide bound Ab-42 peptides effectively and irreversibly in an in vitro study (Sundaram et al. 2008) . We showed that polyethylene glycol (PEG) conjugates bearing several copies of ffvlk can be useful as diagnostic and therapeutic agents for Alzheimer's disease. Essentially, these detox gels are made by covalently linking a particular RI peptide to poly(ethylene glycol) polymer chains. PEG was chosen as the building block of the new hydrogel-forming polymers. PEG is a non-toxic, non-immunogenic, highly water soluble polymer. Linking peptides (or proteins) to PEG is called pegylation and this causes improved pharmacokinetics, increased circulation time and decreased toxicity.
In the present study, we attempted to determine the therapeutic effect of our detox gel in AD model mice (APPSWE-Tg2546) (Hsiao et al. 1996) . Results showed that our detox gel treatment led to a reduction of brain amyloid burden by while simultaneously improving memory parameters without any observable immune response.
Materials and Methods
Peptides and Other Chemicals RI-tetramer peptide was synthesized at the Keck Foundation at Yale University, as described previously (Sundaram et al. 2008) . Tetramer peptide containing four copies of peptide ffvlk (composed of D-amino acids and has the reverse sequence of Ab16-20 peptide). Lysine was added to the C terminals and b alanine was added to provide turns. The peptides were purified by reverse-phase HPLC and analyzed by MALDI-TOF to confirm structure.
Detox Gel 25 mg MAL-PEG-NHS (5,000 mol wt) was dissolved in 2.5 ml of 20 mm phosphate buffer, pH 7.4. To this, add 7.5 mg of tetramer peptide. Nitrogen was bubbled through all solutions to remove oxygen. The solution was mixed at room temperature for 2 h and dialyzed with a 20 kD cutoff dialysis membrane. We injected 100 ll/mouse/injection. Therefore, each injection contained 300 lg of the tetramer peptide.
Animals
The detox gels were administered to heterozygous APPSWE amyloid precursor protein (APPSWE-Tg2546) mouse model (Hsiao et al. 1996) . These mice show rapid increases in Ab levels at approximately 6 months of age with Ab deposition developing in the following months although extensive amyloid burden is usually not observed until the animals are well into their second year (Kawarabayashi et al. 2001 ). Mice were 20-24 weeks old when experiment was started. The animals were maintained on a 12-h light:12-h dark cycle, and animal care was in accordance with institutional guidelines in AAALAC approved facilities at Taconic Farms, NY. The mice received subcutaneous injections (100 ll) of detox gel. One injection per month was given the first 3 months followed by 2 biweekly injections thereafter (Table 1 ). The mice went through the Y maze behavioural test before drug administration and prior to euthanasia. A group of mice received no injections and served as control mice group. Mice were anaesthetized with sodium pentobarbital (150 mg/kg, i.p.), perfused transaortically with phosphate buffer, and the brains processed as described previously (Kawarabayashi et al. 2001 ). The right hemisphere was immersion-fixed in paraformaldehyde, whereas the left hemisphere was snapfrozen for measurements of Ab levels.
Tissue Homogenization and Sandwich ELISA Assay for Ab Levels Extraction and measurement of Ab from brain tissue was performed as described (Kawarabayashi et al. 2001) . Briefly, frozen hemi brains were homogenized followed by sonication in a 10 fold volume of Tris-buffered saline (TBS-20 mM Tris and 137 mM NaCl, pH 7.6) containing 2% SDS and protease inhibitors (complete protease inhibitor cocktail, Boehringer Mannheim, Mannheim, Germany) followed by centrifugation at 100,0009g for 1 h at 4°C. The supernatant was then removed, and the pellet was sonicated with 70% formic acid (FA) and centrifuged at 100,0009g for 20 min at 20°C. FA extracts (supernatants) were neutralized by diluting (1:20) into 1 M Tris phosphate buffer, pH 11. The supernatants were vacuumdried and solubilized in TBS. Extracts of brain were coated on 96-well micro titer plates (MaxiSorb; Nunc, Rosklide, Denmark) in triplicates (5 ll/well). The wells were blocked with 3% gelatine (1 h at 37°C) following which the biotinylated monoclonal b-amyloid antibody 12F4 (Covance, WI that recognises only the Ab-42 peptide) was added at a 1:1,000 dilution and plates incubated for 1 h at 37°C. The wells were then washed and probed with streptavidinhorseradish peroxidase conjugate (Amersham Biosciences, at 1:1,000 dilution), for 1 h at 37°C. Color was developed and read at 620 nm by TMB substrate (KPL, Gaithersburg, MD) as per manufacturer's instructions. Standard curves of Ab-42 (AnaSpec, CA) scaling from 6 to 400 pmol were used.
Measurement of Ab-42 in Serum by ELISA
In order to examine the validity of our sink hypothesis, we measured the levels of Ab-42 in the sera obtained from these mice at the end of the experiment. This was accomplished by an ELISA using immobilized sera (at 1:10 dilution). After blocking, serum Ab-42 was probed with a biotinylated monoclonal antibody 12F4 (at 1:1,000 dilution, Covance, WI). ELISA was performed as mentioned in the earlier section. Standard curves of Ab-42 (AnaSpec, CA) were used.
Immunohistochemistry
Serial sections (5 lm) were cut sagittally through the mouse hemisphere embedded in paraffin with rotary microtome. Every third section of each series of sections will be mounted on Superfrost Plus slide. All sections were processed for amyloid beta-immunohistochemistry using a monoclonal mouse anti-human beta-amyloid antibody (G48, Covance, WI). In brief, following deparaffinizing in xylene, sections were rinsed in graded ethanols and then rehydrated to distilled water. After inactivating the endogenous peroxidase activity with hydrogen peroxidase and antigen retrieval as described in the manufacturer's literature, sections were incubated in 0.01 M phosphate buffered saline (pH 7.4) containing normal blocking serum, BSA (Jackson ImmunoResearch Labs, West Grove, PA), Triton X-100 and the specific antibody (1:200) for overnight at 4°C. The immunoreaction products were then visualized with avidin-biotin complex Vectastin elite ABC kit (Vector Lab., Burlingame, CA) and 3,3 0 -diaminobenzidine as a chromogen. After thorough rinses in distilled water, sections were counterstained with hematoxylin. Following dehydration in ethanol, sections were cleared in xylene, and coverslipped in Permount Ò (Fisher Scientific, Fair Lawn, NJ). Immunohistology services were provided by FD Neurotechnologies (Maryland) and pathology assistance was provided by Veterinary Histology Consultants (Connecticut).
Behavioural Testing-Y Maze
This test is performed as described (King and Arendash 2002) . Briefly, the mice will be handled gently, holding by Group 1 (n = 9) 100 ll detox gel with RI peptide (tetramer) 1 injection on weeks 1, 5, 9, 11, and 13
Group 2 (n = 9) No injection None tail and let to rest on arm, taking care not to let mouse plunge down head first into maze. Mice were individually placed in the centre of a Y maze, with all three arms available for exploration, for a period of 8 min. The Y maze is a three-arm maze with equal angles between all arms. The percentage of triads in which all three arms are represented were recorded as an alternation to estimate short-term memory of the last arms entered. After the test, data was transferred from hard copy to Excel spreadsheet. An alternation is defined as a visit to all three arms without re-entry (ABC, ACB, BAC, BCA, CAB or CBA). Mice were tested before and after detox gel administration.
Antibody Levels
Antibody levels were determined at 1:10, 1:100 and 1:1,000 dilutions of serum using ELISA as described previously (Sigurdsson et al. 2001) , in which tetramer peptide was coated onto micro titer wells (100 ng per well), stored at 37°C overnight, and then blocked with buffer containing 3% gelatine in 19 Tris-buffered saline for 2 h at room temperature. Diluted sera (1:10, 1:100 and 1:1,000) were added to antigen-coated wells and incubated for 2 h at room temperature. After washing with 0.1% Tween 20 in Tris-buffered saline, plates were incubated with HRP-labelled goat anti-mouse secondary antibodies (Kirkegaard and Perry, Gaithersburg, MD at 1:5,000 dilution) for 2 h at room temperature and plates were again washed with TBST. After adding HRP substrate solution (Kirkegaard and Perry, Gaithersburg, MD), absorbance was read at 620 nm. Antibody levels to Ab-42 were also measured similarly where Ab-42 (instead of tetramer peptide) was coated on microtiter plates (100 ng per well) and treated as above.
Statistical Analysis
All results were expressed as the mean ± SD for each group. The Mann-Whitney test was used to compare two sets of data and statistical significance (P value) was calculated.
Results
We have already demonstrated that effectiveness of a novel ''detox gel'' system in binding Ab peptides in vitro (Sundaram et al. 2008) . In the present study, an attempt was made to determine its efficacy in a mouse model of AD (APPSWE-Tg2546). We injected the APPSWE (Tg2546) mice with our detox gels when the mice were 6 months old over a span of 4 months (n = 9). Uninjected mice served as control (n = 9). At the end of the study, brain and serum samples were collected and analysed. Memory tests (Y maze) were performed in all the mice 1 week prior to the first injection and 1 week after the last injection. The results are presented below.
Effect of Detox Gel on the Body Weight in APPSWE (Tg2546) Mice
We examined the changes of body weight in the detox gel treated mice and non-treated mice. Body weight was measured at the beginning and end of the study. There was gain in body weight in the detox gel treated mice as shown in Fig. 1 (26 ± 2.5 g before treatment to 30 ± 3.4 g at the end of treatment with P \ 0.002). In the untreated group however, the mice gained no weight (27.1 ± 2.3 g at the beginning to 27.5 ± 3.1 g at the end of the study).
Quantitative Analysis of Ab-42 in Brain
Ab in brain was extracted by methods described in experimental methods section. Ab-42 levels were measured in brain extracts by an ELISA using a commercial antibody. The two-step extraction method that we employed yields total Ab. The results show that there is a reduction in the level of total Ab-42 by 30% in the group of mice that received the detox gel when compared to the untreated group ( Fig. 2) with a statistical significance (P \ 0.001).
Measurement of Ab-42 in Serum by ELISA
In order to examine the validity of our sink hypothesis, we measured the levels of Ab-42 in the sera obtained from these mice at the end of the experiment. This was accomplished by an ELISA using immobilized sera (at 1:10 dilution). The results indicate that there is a 50% increase in levels of circulating Ab-42 in the treated group when compared to the Detox gel treated Mice Untreated Mice Fig. 1 Body weight of control and AD mice before and after treatment with detox gel. Weight of mice at the beginning and at the end of the study in the detox gel treated and untreated control group (n = 4 in control and n = 5 in detox gel treated group) untreated group (Fig. 3) . Thus the data indicate efflux of Ab-42 from brain to periphery, which is a phenomenon, observed by other studies using Ab-42 sequestering agents. This observation confirms our sink hypothesis.
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Immunohistochemistry of Brain Sections
Immunohistology was performed on brain sections and analysed. A commercial antibody specific to Ab was used.
The results are promising in that there is a reduction in size of plaques in the brain of detox gel treated mice when compared to uninjected control mice sections. Ab immunoreactive plaque load (mean plaque size measured as lm 2 ; mean ± SD) was significantly reduced by detox gel treatment (detox gel treated, 299 ± 107 lm 2 ; untreated, 483 ± 139 lm 2 ). Comparing mean plaque sizes across treated and untreated groups reveals a decreasing trend in plaque size of treated mice. Four out of four animals in the untreated group have overall plaques sizes greater than the average size of 400 lm 2 for the entire group compared to only one animal out of five the treated group. A sample set of pictures representing four largest plaques shown confirms this observation (Fig. 4) . To test for the possibility that the tetramer peptide crossed over the BBB, and resulting in false positive signals in IHC, we performed an ELISA using immobilized tetramer employing the same antibody that was used in IHC. The results showed that this antibody was unable to react to tetramer peptide thus suggesting the positive signal obtained in IHC was specific to intrinsic Ab.
Behavioural Test
Detox gel treated mice and control mice were assessed on the Y maze cognitive test before and after treatment. Y maze test is a qualitative measure of intact working memory in animals that tend to explore new parts of an environment instead of returning to known parts immediately (alternation). Y maze is used to assess (without food deprivation or other aversive procedures) the normal navigation behaviours of rodents and is particularly useful as an initial test of spatial memory function in mice. The Y maze test is based on the natural drive of rodents to explore novel environments. Success in this test is indicated by a high rate of alternation (spontaneous alternation) indicating that the animals can remember which arm was entered last. The results show that there is a difference between the detox gel injected mice when compared to the non-injected counterpart (Fig. 5) . The percentage of alteration was 47.5% before the injections. This improved to 61.4% after detox gel regimen. These results are statistically significant. The uninjected control mice started off with a score of 62%, which decreased over the course of the study to 49%, suggesting progressive memory loss upon aging. In this context, the observed improvements in the treated mice from initial and final measurements appear to be even more pronounced.
Test for Immunogenicity to the Detox Gels
We tested for the presence of antibodies to our peptide to determine if there was any immune response elicited. If there was an antibody response, the antibodies might have Immobilized sera (at 1:10 dilution) was plated in triplicates. After blocking, wells were probed with a biotinylated monoclonal antibody 12F4 (at 1:1,000 dilution, Covance, WI). Detection was done using a streptavidin-horseradish peroxidase conjugate (Amersham Biosciences), followed by TMB substrate (KPL, Gaithersburg, MD). Standard curves of Ab-42 (AnaSpec, CA) scaling from 6 to 400 pmol was used (n = 8 for treated and untreated group with a statistical significance of P \ 0.002 was obtained by a MannWhitney test)
been responsible for the observed reduction of Ab-42 peptide in treated mice. Antibody levels to tetramer RI peptide measured in sera (at various dilutions) by a standardized ELISA. As can be seen in the Fig. 6 , injection of detox gel did not induce any measurable antibody response even at the lowest dilution (1:10). This ELISA was repeated replacing the RI tetramer peptide with the Ab-42 peptide. The results showed that there were no antibodies made against the Ab-42 (data not shown).
Discussion
AD is a growing problem that exacts a tremendous monetary and human toll, significantly lowering the quality of life for those affected directly and indirectly. The treatment of AD is an unmet medical need for which no palliative or curative therapies have consistently been shown to work. We hypothesized that the detox gel consisting of a tetrameric version of the retro-inverse peptide ffvlk linked to PEG will act according to the principles of the peripheral sink mechanism to irreversibly bind and retain the toxic Ab from the surroundings. We have demonstrated proof of concept for this detox gel system in vitro (Sundaram et al. 2008) . The present study is a logistic extension of our in Detox gel treated mice Untreated mice Fig. 6 Immunogenicity to the detox gel in AD mice. Antibody response in mice injected with detox gel and mice that did not receive any injections. ELISA plates were coated with RI tetramer (100 ng per well), stored at 37°C overnight, and then blocked with buffer containing 3% gelatin in 19 Tris-buffered saline for 2 h at room temperature. Diluted sera (1:10, 1:100 and 1:1,000) were added in triplicate to antigen-coated wells and incubated for 2 h at room temperature. After washing with 0.1% Tween 20 in Tris-buffered saline, plates were incubated with HRP-labelled anti mouse secondary antibodies (Kirkegaard and Perry, Gaithersburg, MD at 1:5,000 dilution) for 2 h at room temperature. After adding HRP substrate solution (Kirkegaard and Perry, Gaithersburg, MD), absorbance was read at 620 nm. Values are expressed as mean ± SD for n = 8 in control and n = 9 in detox gel treated group vitro studies in that it attempts to test our detox gel in a well established AD mice model (Hsiao et al. 1996) . Our concept relies on RI peptides, in which all D-amino acids are used and the change in chirality is counteracted by reversing the primary sequence, contain inter-amino acid bonds that are the most closely related isosteric replacements for the original peptide bond. These modifications preserve the major structural characteristics of the peptide backbone despite changing the native structure. Consequently, retroinverse peptides generally have increased stability as has been demonstrated for a number of peptides, including enkephalin, glutathione, substance P, gastrin, and atrial natiuretic peptide (Chorev and Goodman 1995; Dintzis et al. 1993; Herve et al. 1997) . Studies have shown that the RI peptide ffvlk derived from the native sequence KLVFF binds Ab with great affinity thus showing that retro inversion does not alter its binding properties. We incorporated our retroinverse peptide into a PEG based hydrogel formulation to help prolong its half life and reduce the probability of immunogenicity. The detox gel is injected subcutaneously into the mice and attracts Ab peptides thus acting like a sink.
In AD, there is a tendency for loss of body weight with progression of disease Gordon 2008: Holcomb et al. 1998) . In the present study, we have observed a similar phenomenon in the uninjected controls. Interestingly, our detox gel treated mice gained weight over time. This observation appears to be a favourable outcome since it indicates reversal to normal physiology.
The data obtained on levels of Ab-42 from brain extracts showed a 30% reduction in detox gel treated mice. This suggests clearance of Ab-42 by the sequestering ability of our detox gel. The results further indicate that there is a 50% increase in levels of circulating Ab-42 in the treated group when compared to the untreated group. This observation confirms efflux of Ab-42 from brain to periphery, a phenomenon observed by other studies using Ab-42 sequestering agents (Demattos et al. 2002) and thus confirms our sink hypothesis. Consequently, immunohistology data also confirmed this observation thus providing additional line of evidence. Additionally, overall size of brain plaques in the detox gel treated mice was smaller than those from uninjected mice. This could be attributed to the reduced amount of Ab peptides in brain of treated mice.
Improvement in memory correlates in treated mice was observed as evidenced by an increase in the percentage of spontaneous alteration. As the plaque load in brain increases, the spatial memory capacity (% alteration) decreases. In detox gel treated mice, the Ab-42 load decreased as seen by ELISA and immunohistochemistry and this might have contributed to the improved alteration in this group. On the other hand, control mice showed a significant decrease in their alteration behaviour, which shows further progression in these mice.
Immunogenicity is one of the major adverse effects observed in other studies using immunotherapy to treat AD. We addressed this concern by examining the immune responses against detox gel treatment. We screened the sera obtained from the treated mice for the presence of antibody to the injected tetramer peptide. The results indicate that our formulation did not elicit an immune response. Tests to detect antibodies to Ab peptides also proved negative results. The observed results confirm that the detox gel treatment induce a non-immune based sequestering of Ab peptides. This is consistent with our sink hypothesis. Further, the lack of immunogenicity in response to our detox gel therapy is in direct contrast to other antibody based therapies that failed due to immune reactions (Bayer et al. 2005; Orgogozo et al. 2003) .
Conclusion
The present study shows that treatment with detox gel in AD mice can be effective as a therapeutic method for lowering Ab levels in the APPSWE mice (Tg2546). The high affinity sequestering ability combined with the lack of immunogenicity and capacity to improve memory parameters make it an interesting drug candidate for the treatment of AD. Thus our detox gel therapy might become a welcome non-immune based therapy with a future in human clinical settings.
